Huntsman Cancer Institute/ University of Utah Network Lead Academic Participating Site Application

项目总结/摘要 作为美国国家癌症研究所（NCI）网络牵头学术参与机构（NLAPS），亨斯迈癌症研究所（Huntsman Cancer） 研究所（HCI）将为国家临床试验网络（NCTN）提供领导和强大的应计费用 程序.正如我们之前作为NCI U10资助的NLAPS合作伙伴所取得的成功所证明的那样，HCI NLAPS将 促进与SWOG、NRG肿瘤学相关的临床试验的开发和实施， 肿瘤临床试验联盟（ALLIANCE）NCTN组，以及临床试验的实质性增加 整个NCTN的试验HCI NLAPS的执行团队在合作方面具有良好的资格和经验， 创新专项项目开展情况进行专题PI，大卫加夫尼，医学博士，博士，是一位放射肿瘤学家，具有悠久的领导历史， 参加NCTN的活动。HCI的教师通过以下方式大大提高了NCTN计划的领导力 参与指导委员会、工作队和小组活动。在过去的四年里，三名HCI教师 是国家主要研究者（PI，研究主席）;两名教员是未决试验的国家PI。 HCI对参与NCTN试验有着坚定的承诺。2017年，18%（96/532）的HCI 对NCTN试验进行了治疗累积，并且一贯地，>50个NCTN治疗试验是开放的， 包括罕见病试验2016年，所有HCI试验中有27%（n=67）用于罕见癌症。HCI看到了一个更大的 在过去的U10资助赠款周期中，NCTN应计费用增长超过50%：在赠款年1- 4中从61增加到96。 HCI有一个充满活力和不断增长的临床试验计划，与犹他州大学的坚定承诺， 大量的慈善支持，最先进的设施，一个专门的癌症医院，和一个集中的 其临床研究企业的基础设施坐落在新的，连续的空间。我们的中心也有独特的 对临床研究有价值的资产，包括农村和美洲原住民人口，NCI中心 定量成像卓越，和犹他州人口数据库，一个强大的相互联系的人口- 根据家谱数据和全州的医疗和生命记录。 2015年，HCI晋升为综合癌症中心，获得了 “非常”。坐落在犹他州大学，在西部山区，HCI唯一的学术医疗中心 吸引了来自犹他州、爱达荷州、内华达州、蒙大拿州和怀俄明州的癌症临床试验患者， 并为这些患者群体提供近乎独家的访问。作为一个NLAPS，HCI将是一个强大的，坚定的， 作为NCTN计划的持续合作伙伴，NCTN是一个以专业知识，领导力和 主动应计。HCI将积极工作，以确保NCTN的合作努力取得成功， 根除癌症

PROJECT SUMMARY/ABSTRACT As a National Cancer Institute (NCI) Network Lead Academic Participating Site (NLAPS), Huntsman Cancer Institute (HCI) will provide leadership and robust accruals for the National Clinical Trials Network (NCTN) Program. As evidenced by our prior success as a NCI U10-funded NLAPS partner, the HCI NLAPS will contribute to the development and conduct of clinical trials in association with SWOG, NRG Oncology, and Alliance for Clinical Trials in Oncology (ALLIANCE) NCTN Groups, as well as substantial accrual to clinical trials across the entire NCTN. The HCI NLAPS executive team is well-qualified and experienced in cooperative group research. The PI, David Gaffney, MD, PhD, is a radiation oncologist with a long history of leadership and participation in NCTN activities. HCI's faculty adds significantly to the leadership of the NCTN program through participation on steering committees, task forces, and group activities. In the past four years, three HCI faculty were national principal investigators (PIs, study chairs); two faculty members are national PIs of pending trials. HCI has a strong, established commitment to participation in NCTN trials. In 2017, 18% (96/532) of HCI therapeutic accruals were made to NCTN trials and, consistently, >50 NCTN therapeutic trials are open, including rare disease trials. In 2016, 27% of all HCI trials (n=67) were for rare cancers. HCI saw a greater than 50% growth in NCTN accruals in the past U10-funded grant cycle: from 61 to 96 in grant years 1- 4. HCI has a vigorous and growing clinical trials program, with strong commitment from the University of Utah, substantial philanthropic support, state-of-the-art facilities, a dedicated Cancer Hospital, and a centralized infrastructure for its clinical research enterprise housed in new, contiguous space. Our Center also has unique assets of value to clinical research, including rural and Native American populations, an NCI Center for Quantitative Imaging Excellence, and the Utah Population Database, a powerful interlinkage of population- based genealogical data and statewide medical and vital records. In 2015, HCI advanced to Comprehensive Cancer Center status, receiving an overall merit descriptor of `Exceptional'. Housed at the University of Utah, the only academic medical center in the Mountain West, HCI draws cancer clinical trial patients from across Utah, as well as from Idaho, Nevada, Montana, and Wyoming, and provides near-exclusive access to this patient population. As a NLAPS, HCI will be a strong, committed, and sustaining partner to the NCTN program as a cancer center characterized by expertise, leadership, and active accrual. HCI will work vigorously to ensure the success of the NCTN's cooperative endeavors to eradicate cancer.